Literature DB >> 24726744

Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.

Bryan M Burt1, Robert B Cameron2, Nathan M Mollberg3, Andrzej S Kosinski4, Paul H Schipper5, Joseph B Shrager1, Wickii T Vigneswaran6.   

Abstract

BACKGROUND: To date, reported surgical morbidity and mortality for pleurectomy/decortication and extrapleural pneumonectomy performed for malignant pleural mesothelioma primarily represent the experience of a few specialized centers. For comparison, we examined early outcomes of pleurectomy/decortication and extrapleural pneumonectomy from a broader group of centers/surgeons participating in the Society of Thoracic Surgeons-General Thoracic Database.
METHODS: All patients in the Society of Thoracic Surgeons-General Thoracic Database (version 2.081, representing 2009-2011) who underwent pleurectomy/decortication or extrapleural pneumonectomy for malignant pleural mesothelioma were identified. Patient characteristics, morbidity, mortality, center volume, and procedure were examined using univariable and multivariable analyses.
RESULTS: A total of 225 patients underwent pleurectomy/decortication (n = 130) or extrapleural pneumonectomy (n = 95) for malignant pleural mesothelioma at 48 centers. Higher volumes of procedures (≥5/y) were performed at 3 pleurectomy/decortication and 2 extrapleural pneumonectomy centers. Patient characteristics were statistically equivalent between pleurectomy/decortication and extrapleural pneumonectomy groups, except those undergoing extrapleural pneumonectomy were younger (63.2 ± 7.8 years vs 68.3 ± 9.5 years; P < .001) and more likely to have received preoperative chemotherapy (30.1% vs 17.8%; P = .036). Major morbidity was greater after extrapleural pneumonectomy, including acute respiratory distress syndrome (8.4% vs 0.8%; P = .005), reintubation (14.7% vs 2.3%; P = .001), unexpected reoperation (9.5% vs 1.5%; P = .01), and sepsis (4.2% vs 0%; P = .03), as was mortality (10.5% vs 3.1%; P = .03). Multivariate analyses revealed that extrapleural pneumonectomy was an independent predictor of major morbidity or mortality (odds ratio, 6.51; P = .001). Compared with high-volume centers, increased acute respiratory distress syndrome was seen in low-volume centers performing extrapleural pneumonectomy (0% vs 12.5%; P = .05).
CONCLUSIONS: Extrapleural pneumonectomy is associated with greater morbidity and mortality compared with pleurectomy/decortication when performed by participating surgeons of the Society of Thoracic Surgeons-General Thoracic Database. Effects of center volume require further study.
Copyright © 2014 The American Association for Thoracic Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24726744     DOI: 10.1016/j.jtcvs.2014.03.011

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  26 in total

1.  Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.

Authors:  Ori Wald; David J Sugarbaker
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Authors:  Fauzia Shaikh; Marjorie G Zauderer; Donata von Reibnitz; Abraham J Wu; Ellen D Yorke; Amanda Foster; Weiji Shi; Zhigang Zhang; Prasad S Adusumilli; Kenneth E Rosenzweig; Lee M Krug; Valerie W Rusch; Andreas Rimner
Journal:  J Thorac Oncol       Date:  2017-03-21       Impact factor: 15.609

3.  Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.

Authors:  Chi-Fu Jeffrey Yang; Brandon W Yan; Robert Ryan Meyerhoff; Shakir M Saud; Brian C Gulack; Paul J Speicher; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  Clin Lung Cancer       Date:  2016-03-17       Impact factor: 4.785

4.  Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.

Authors:  Wickii T Vigneswaran; Diana Y Kircheva; Adrian E Rodrigues; Sydeaka Watson; Amy Durkin Celauro; Berkley Rose; Hedy L Kindler; Aliya N Husain
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

5.  Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Paolo Olivo Lausi; Roberto Giobbe; Paraskevas Lyberis; Enrico Ruffini; Alberto Oliaro
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 6.  Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Authors:  Hasan Fevzi Batirel
Journal:  Ann Transl Med       Date:  2017-06

Review 7.  A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.

Authors:  Isabelle Opitz; Walter Weder
Journal:  Ann Transl Med       Date:  2017-06

8.  Pleurectomy and decortication.

Authors:  Tedi Vlahu; Wicki T Vigneswaran
Journal:  Ann Transl Med       Date:  2017-06

Review 9.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

10.  MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Authors:  Michaela B Kirschner; Yuen Yee Cheng; Nicola J Armstrong; Ruby C Y Lin; Steven C Kao; Anthony Linton; Sonja Klebe; Brian C McCaughan; Nico van Zandwijk; Glen Reid
Journal:  Mol Oncol       Date:  2014-12-02       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.